Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • geographic atrophy

    - PMLiVE

    Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

    Around 55,100 cases of prostate cancer are diagnosed in the UK every year

    - PMLiVE

    Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

    Approximately 614,000 people are diagnosed with bladder cancer globally every year

    - PMLiVE

    Astellas’ Vyloy combination approved by MHRA as first-line gastric cancer treatment

    Approximately 6,600 new cases of the disease are diagnosed in the UK every year

    - PMLiVE

    Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

    The company will gain the rights to use 4DMT’s gene therapy vector for at least one target

    - PMLiVE

    Astellas to acquire Iveric Bio for approximately $5.9bn

    The deal includes the US drugmaker’s lead candidate for geographic atrophy

    - PMLiVE

    Positive results for Astellas’ zolbetuximab in gastric cancer published in The Lancet

    Over one million new cases of gastric cancer were diagnosed globally in 2020

    - PMLiVE

    Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

    Will pay $100m upfont and pledges $210m in milestone payments

    - PMLiVE

    The power of pharma businesses to drive social change

    The importance of CSR programmes

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links